Skip to content
sellWeak cluster of 210b5-1 plan

Watanabe Todd Franklin sold $228k of ARQT

See Remarks at Arcutis Biotherapeutics, Inc.. 15,000 shares at an average of $15.17, traded Dec 20, 2024, filed Dec 23, 2024.

Warning score
16
Value
$228k
15,000 shares
Holdings after
823,430
-2% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Rows in this filing

Every transaction in Form 4 0001787306-24-000172, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Dec 20, 2024SOpen-market sale
Common Stock10b5-1
-15,000$15.17$228k823,430Dec 23, 2024

Related signals

Other insiders at Arcutis Biotherapeutics, Inc. and this insider’s other filings.

ScoreSideCompanyInsiderValueSharesFiled
3Weaksell 210b5-1ARQT
Arcutis Biotherapeutics, Inc.
Burnett Patrick
See Remarks
$24k1,691
18Weakbuy 2ARQT
Arcutis Biotherapeutics, Inc.
Watanabe Todd Franklin
See Remarks
$21k6,038
21Weaksell 310b5-1ARQT
Arcutis Biotherapeutics, Inc.
Welgus Howard G.
director
$125k10,000
23Weakbuy 2ARQT
Arcutis Biotherapeutics, Inc.
Matsuda Masaru
See Remarks
$19k5,657
10WeakbuyARQT
Arcutis Biotherapeutics, Inc.
Edwards Larry Todd
See Remarks
$7,7671,093
31Weaksell 4ARQT
Arcutis Biotherapeutics, Inc.
Burnett Patrick
See Remarks
$163k16,023
10Weaksell 410b5-1ARQT
Arcutis Biotherapeutics, Inc.
Matsuda Masaru
See Remarks
$17k1,775
46Moderatesell 5ARQT
Arcutis Biotherapeutics, Inc.
Burnett Patrick
See Remarks
$713k69,226
50Moderatesell 5ARQT
Arcutis Biotherapeutics, Inc.
Curran Terrie
director
$94k8,687
21Weaksell 510b5-1ARQT
Arcutis Biotherapeutics, Inc.
Burnett Patrick
See Remarks
$134k15,441

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.